Raid Aljumaily to Follow-Up Studies
This is a "connection" page, showing publications Raid Aljumaily has written about Follow-Up Studies.
Connection Strength
0.104
-
Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors. Clin Cancer Res. 2020 12 01; 26(23):6196-6203.
Score: 0.037
-
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial. Ann Oncol. 2019 10 01; 30(10):1613-1621.
Score: 0.035
-
A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors. Invest New Drugs. 2019 06; 37(3):461-472.
Score: 0.032